Klin Farmakol Farm. 2011;25(2):64-70

Overview of current treatment options in antiresorptive

Václav Vyskočil
Fakultní nemocnice Plzeň, II. interní klinika, Osteocentrum Plzeň

We currently have four groups of drugs with a purely antiresorptive effect:

1. the oldest and longest-studied drug, which is undoubtedly Calcitonin

2. the group of selective blockers of estrogen receptors, represented by Raloxifene

3. the group of bisphosphonates of II. and III. generation in oral and intravenous modifications

4. the biological treatment, where is the sole representative of denosumab

The author analyzes studies that have monitored these drugs, including results on the fractures reduction.

Keywords: definition of osteoporosis, calcitonin, estrogen receptors, raloxifene, bisphosphonates, denosumab

Published: June 20, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vyskočil V. Overview of current treatment options in antiresorptive. Klin Farmakol Farm. 2011;25(2):64-70.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795. Go to original source... Go to PubMed...
    2. Wiles MD, Moran CG, Sahota O, Moppett IK. Nottingham Hip Fracture Score as a predictor of one year mortality in patients undergoing surgical repair of fractured neck of femur. J Anaesth. 2011; 106(4): 501-504. Go to original source... Go to PubMed...
    3. Seeman E. The dilemma of osteoporosis in men. American Journal of Medicine 1995; 98(Suppl 1A): 75S-787S. Go to original source... Go to PubMed...
    4. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991; 151: 2026-2032. Go to original source...
    5. Kannus P, Parkkari J, Sievanen H, Heinonen A, et al. Epidemiology of hip fractures. Bone 1996; 18: 57S-61S. Go to original source... Go to PubMed...
    6. Fleisch H. Bisphosphonates in bone diseases. Third Edition. New York: The Parthenon Publishing Group, 1997.
    7. Gonnelli S, Rottoli P, Capollaro C, et al. Prevention of corticosteroid-induced osteoporosis with alendronat in sarcoid patients. Calcif Tiss Int 1997; 61: 382-385. Go to original source... Go to PubMed...
    8. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109(4): 267-276. Go to original source... Go to PubMed...
    9. Barrett-Connor E, Cauley JA, Kulkarni PM, et al. Risk benefit profile for raloxifene: 4year data from the Multiple Outcomes of Raloxifen Evaluation (MORE) randomized trial. J Bone Miner Res 2004; 19: 1270-1275. Go to original source... Go to PubMed...
    10. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four year results from the MORE randomized trial. JAMA 2002; 287: 847-857. Go to original source... Go to PubMed...
    11. Siris ES, Harris ST, Eastell R, Zanchetta JR, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res. 2005; 20(9): 1514-1524. Go to original source... Go to PubMed...
    12. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the longterm effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475-1480. Go to original source... Go to PubMed...
    13. Meunier PJ, Arlot M, Chavassieux P, Recker RR, Kimmel D, Yates AJ. The effects of alendronate on bone turnover and bone quality. Int J Clin Pract 1999; 101(Suppl): 14-17.
    14. Roschger P, Rinnerthaler S, Yates J, et al. Alendronate Increases Degree and Uniformity of Mineralization in Cancellous Bone and Decreases the Porosity in Cortical Bone of Osteoporotic Women. Bone 2001; 29: 185-191. Go to original source... Go to PubMed...
    15. Bloebaum RD, Skedros JG, Vajda EG, et al. Determining mineral content variations in bone using backscattered electron imaging. Bone 1997; 20: 485-490. Go to original source... Go to PubMed...
    16. Boyde A, Compston JE, Reeve J, et al. Effect of estrogen suppression on the mineralization density of iliac crest biopsies in young women as assessed by backscattered electron imaging. Bone 1998; 22: 241-250. Go to original source... Go to PubMed...
    17. Boyde A, Jones SJ, Aerssens J, et al. Mineral density quantitation of the human cortical iliac crest by backscattered electron image analysis: Variations with age, sex, and degree of osteoarthritis. Bone 1995; 16: 619-627. Go to original source... Go to PubMed...
    18. Rinnerthaler S, Roschger P, Jakob HF, et al. Scanning small angle X-ray scattering analysis of human bone sections. Calcif Tissue Int 1999; 64: 422-429. Go to original source... Go to PubMed...
    19. Roschger P, Fratzl P, Eschberger J, et al. Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone 1998; 23: 319-326. Go to original source... Go to PubMed...
    20. Roschger P, Fratzl P, Klaushofer K, et al. Mineralization of cancellous bone after alendronate and sodium fluoride treatment: A quantitative backscattered electron imaging study on minipig ribs. Bone 1997; 20: 393-397. Go to original source... Go to PubMed...
    21. Fratzl P, Schreiber S, Roschger P, et al. Effects of sodium fluoride and alendronate on the bone mineral in minipigs: A small-angle X-ray scattering and backscattered electron imaging study. J Bone Miner Res 1996; 11: 248-253. Go to original source... Go to PubMed...
    22. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000; 85: 4118-4124. Go to original source... Go to PubMed...
    23. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the Early Postmenopausal Intervention Cohort Study: a randomized trial. Ann Intern Med 1999; 131: 935-942. Go to original source... Go to PubMed...
    24. Ravn P, Weiss SR, Rodriguez-Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 2000; 85: 1492-1497. Go to original source...
    25. Luckey MM, Gilchrist N, Bone HG, et al. Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 2003; 101: 711-721. Go to original source... Go to PubMed...
    26. Shane E, Burr D, Ebeling PR, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010; 25(11): 2267-2294. Go to original source... Go to PubMed...
    27. Miller PD, Brown JP, Siris ES, et al. A comparative trial of risedronate versus etidronate in the treatment of patients with Pageťs disease of bone. Am J Med 1999; 106: 513-520. Go to original source... Go to PubMed...
    28. Hosking DJ, Eusebio RA, Chines AA. Pageťs disease of bone: reduction of disease activity with oral risedronate. Bone 1998; 22: 51-55. Go to original source... Go to PubMed...
    29. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologie and densitometrie effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994; 15: 41-49. Go to original source... Go to PubMed...
    30. Cohen-Solal ME, Roux C, Valentin-Opran A, et al. Histomorphometric effect of six month treatment with oral risedronate in patients with multiple myeloma. Bone 1993; 14: 505-509. Go to original source... Go to PubMed...
    31. Mortensen L, Charles P, Bekker PJ, et al. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83: 396-402. Go to original source...
    32. Wallach S, Cohen S, Reid, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int. 2000; 67(4): 277-285. Go to original source... Go to PubMed...
    33. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-1352. Go to original source... Go to PubMed...
    34. Reginster J, Minne HW, Sorensen OH, et al. Eastell R Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos Int 2000; 11: 83-91. Go to original source... Go to PubMed...
    35. McClung MR, Geusens P, Miller PD, et al. Intervention Program Study Group: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. NEJM 2001; 344: 333-340. Go to original source... Go to PubMed...
    36. SPC Bonviva EU/1/03/265/003.
    37. Chesnut Ch, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2005; 21(3): 391-401. Go to original source... Go to PubMed...
    38. Chesnut CH, Skag A, Christiansen C, et al. Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis J Bone Miner Res 2004; 19(8): 1241-1249. Go to original source... Go to PubMed...
    39. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-2082. Go to original source... Go to PubMed...
    40. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004; 15: 423-433. Go to original source... Go to PubMed...
    41. Miller PD, McClung MR, Macovei L, et al. Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis 1-Year Results from the MOBILE Study. J Bone Miner Res 2005; 20: 1315-1322. Go to original source... Go to PubMed...
    42. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006; 65(5): 654-661. Go to original source... Go to PubMed...
    43. Ravn P, Clemmesen B, Riis BJ, et al. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996; 19: 527-533. Go to original source... Go to PubMed...
    44. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54(6): 1838-1846. Go to original source... Go to PubMed...
    45. Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial. Once-yearly zolendronic acid for treatment of postmenopausal osteoporosis. N Eng J Med 2007; 356: 1809-1822. Go to original source... Go to PubMed...
    46. Bone HG, Bolognese MA, Yue CH, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93: 2149-2157. Go to original source... Go to PubMed...
    47. Brown JP Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24: 153-161. Go to original source... Go to PubMed...
    48. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy (STAND). J Bone Miner Res. 2010; 25(1): 72-81. Go to original source... Go to PubMed...
    49. Cummings SR, Martin JS, McClung MR, et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis for the FREEDOM Trial NEJM N Engl J Med 2009: 361. Go to original source... Go to PubMed...
    50. Papapoulos SE, Quandt SA, Liberman UA, et al. Metaanalysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16: 468-474. Go to original source... Go to PubMed...
    51. Vyskočil V. Osteoporóza a ostatní nejčastější metabolická onemocnění skeletu. Praha: Galén; 2009: 507.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.